Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 1,489 | 0.71 |
| pathways Reactome | 5 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 8536
Sealed predictions
- CRY2 in dopamine neurons, braak-0.58 (p 0.101) → -0.37 (p 0.321)receipt 8541
Swarm cases
receipt 8541: CRY2 in dopamine neurons, braak
- power
- full sample -0.42 (p 0.082, n 18), 95% CI -0.74 to +0.06. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.55 (p 0.018, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.66 (p 0.0031, n 18). not the mix.
- skeptic
- leave-one-out range -0.49 to -0.34, sign flips 0; without severely affected donors -0.42 (p 0.082, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CRY2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts